If you’ve been watching Panasonic Holdings (TSE:6752) lately, the launch of the new Technics SL-40CBT and SL-50C Direct Drive Turntables at the CEDIA convention may have caught your eye for good reason. These innovative models blend Technics’ renowned audio quality with modern flair, including wireless connectivity and sleek design, aiming to capture the imagination of both seasoned Hi-Fi users and newcomers eager to upgrade. Anytime a legacy brand doubles down on a resurgent category like...
Nippon Prologis REIT announced a semi-annual dividend of ¥1,801.00 per share, with an ex-date of November 27, 2025 and payment on February 16, 2026, following the board’s recent declaration.
This higher dividend payout highlights management’s continued confidence in the REIT’s cash flow stability and ability to sustain attractive distributions for investors.
We will explore how the new dividend increase shapes Nippon Prologis REIT’s investment narrative and signals management’s outlook on...
Fujitsu (TSE:6702) just signed a strategic partnership with 1Finity and Arrcus to push the boundaries of next-generation network infrastructure. This is more than a simple agreement between firms; it is a move aimed squarely at solving one of today's biggest challenges for tech companies: the explosion of data as AI services become more embedded in society. By teaming up with Arrcus and 1Finity, Fujitsu is looking to make it easier and more cost-effective for businesses to manage the heavy...
Japan Hotel REIT Investment (TSE:8985) just gave markets something to consider by releasing full-year earnings and dividend guidance for 2025, as well as a snapshot of operating results through July. The company expects steady numbers across revenue, net income, and dividends, which gives investors a clearer read on the REIT’s path into next year. With occupancy rates holding strong and revenue per available room showing resilience, it is no surprise that renewed investor interest is...
On August 26, 2025, Eli Lilly announced positive topline results from the Phase 3 ATTAIN-2 trial of orforglipron in adults with obesity or overweight and type 2 diabetes, meeting all primary and key secondary endpoints including significant weight loss, HbA1c reduction, and improvements in cardiometabolic risk factors.
This clinical milestone is significant for Chugai Pharmaceutical as a development partner for orforglipron, strengthening its pipeline and future product prospects through...
